|1.||Lip, Gregory Y H: 14 articles (12/2015 - 11/2013)|
|2.||Beyer-Westendorf, Jan: 6 articles (11/2015 - 01/2012)|
|3.||Werth, Sebastian: 5 articles (11/2015 - 01/2012)|
|4.||Lane, Deirdre A: 3 articles (12/2015 - 05/2015)|
|5.||Weiss, Norbert: 3 articles (11/2015 - 08/2014)|
|6.||Pannach, Sven: 3 articles (11/2015 - 08/2014)|
|7.||Tittl, Luise: 3 articles (11/2015 - 08/2014)|
|8.||Hänsel, Ulrike: 3 articles (11/2015 - 08/2014)|
|9.||Chatterjee, Saurav: 3 articles (11/2015 - 08/2014)|
|10.||Sardar, Partha: 3 articles (11/2015 - 08/2014)|
08/01/2015 - "For patients with a previous hospitalization in cardiology in a tertiary hospital and a diagnosis of atrial fibrillation, the rate of NOAC prescription is low, and the TTR with VKA was poor."
01/01/2014 - "There were 826 patients, mean age 70.6, follow up 591 years, with atrial fibrillation treated with NOAC. "
08/01/2013 - "Anticoagulation in atrial fibrillation: NOAC's the word."
11/01/2014 - "In the near future, however, an increasing number of patients with atrial fibrillation will suffer recurrent stroke despite treatment with nOAC. "
06/01/2014 - "Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). "
10/01/2015 - "In this article, AF risk assessment is discussed and NOAC phase III clinical trials for the prevention of stroke and systemic embolic events are reviewed. "
06/01/2015 - "This study characterizes utilization, effectiveness, and complications of NOAC agents for stroke prophylaxis in the setting of DCCV. "
01/01/2014 - "To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. "
12/01/2013 - "Whereas studies investigating the use of VKA for stroke prevention in the 1990s were carried out by industry-independent institutions, all NOAC-investigating trials were sponsored by the manufacturers of the respective drugs. "
07/15/2013 - "Based on these considerations it is our opinion that studies of NOAC in patients with stroke compared with other prevention strategies, as well as more post marketing surveillance data, are required."
05/05/2014 - "intracerebral haemorrhage), can the anticoagulant effects of the direct NOACs be reversed rapidly and, if so, can NOAC-associated bleeding and complications be minimised and patient outcome improved? "
01/01/2015 - "Data on major and fatal bleeding events was sought from randomized controlled trials of NOAC agents compared to VKAs. "
01/01/2015 - "This systematic review and meta-analysis of randomized controlled trials determines the relative odds of fatal bleeding given that a patient suffered a major bleed while on NOAC versus VKA therapy. "
01/01/2014 - "Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. "
12/01/2013 - "A subgroup analysis from the dabigatran-investigating trial indicated that elderly patients might have a higher risk for extracranial bleeding complications with NOAC than with VKA. "
02/01/2014 - "Gender differences in cerebrovascular accident/systemic embolism (CVA/SE) or major bleeding outcomes with novel oral anticoagulant (NOAC) use are not known. "
01/01/2015 - "NOAC are more efficacious than warfarin for the prevention of stroke and systemic embolism in Japanese patients with NVAF. "
06/01/2015 - "Variables of interest include utilization rates for each NOAC agent stratified by clinical parameters including CHADS2 score, and associated clinical outcomes including cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral arterial embolism (PAE), and bleeding events during 8 weeks of postprocedure follow-up. "
08/15/2013 - "Symptomatic intracerebral hemorrhage (ICH), hemorrhagic transformation (HT) on T2*-weighted MRI, recurrence of stroke or TIA, systemic embolism and any bleeding complications after initiation of NOAC were evaluated. "
10/01/2015 - "Treatment with NOAC compared with warfarin was associated with a significant reduction in the sum of stroke or non-CNS, systemic embolism and major bleeding (odds ratio 0.87; 95% CI: 0.82-0.91). "
07/01/2013 - "To review novel oral anticoagulant (NOAC) trials in the treatment of venous thromboembolism (VTE) and the possible use of risk-stratification tools to guide their use in practice. "
11/01/2014 - "For this narrative review, we searched the PubMed database for recent (January 2008 to week 32 of 2013) clinical studies relating to NOAC use for stroke prevention in atrial fibrillation and for the treatment of acute venous thromboembolism. "
11/01/2014 - "PubMed was searched for recent (January 2008 to week 32 of 2013) clinical studies relating to NOAC use for stroke prevention in atrial fibrillation (AF) and for the treatment of acute venous thromboembolism (VTE). "
01/01/2015 - "Several new oral anticoagulants (NOAC) have been recently studied and approved for the prevention and treatment of venous thromboembolism (VTE) which includes deep vein thrombosis and pulmonary embolism. "
01/01/2013 - "New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without need of laboratory guided dose adjustment. "
|9.||Factor Xa (Coagulation Factor Xa)
|1.||Electric Countershock (Cardioversion)
|2.||Drug Therapy (Chemotherapy)
|3.||Renal Dialysis (Hemodialysis)